FDA Launches Pilot Program for Real-Time Clinical Drug Trials Using AI and Cloud Technology
The Food and Drug Administration (FDA) has announced a new pilot program that utilizes artificial intelligence (AI) and cloud computing to monitor clinical trial data in real time. This initiative aims to significantly reduce the time required for the approval of new drugs, devices, and medications. FDA Commissioner Marty Makary highlighted that the traditional drug approval process, which can take 10 to 12 years, involves substantial 'dead time' due to paperwork and other administrative tasks. The pilot program, which includes trials by AstraZeneca and Amgen, allows for direct data feeds from clinical trials to the FDA, enabling real-time monitoring of clinical endpoints and other significant signals. The FDA's Chief Artificial Intelligence Officer, Jeremy Walsh, emphasized that while the program aims to expedite regulatory decisions, it will not compromise safety standards. 
